SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
3d rendering medical heart in yellow background
Cardiovascular disease
AstraZeneca’s Baxdrostat Pushes Blood Pressure Lower in Phase III Trial
The drug came to AstraZeneca through its acquisition of CinCor Pharma in 2023, with the hopes of beefing up its cardiovascular and kidney disease pipelines.
July 14, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Pictured: Takeda sign at its office in Massachusetts
Neuroscience
Takeda Establishes Lead in Narcolepsy Race With Back-to-Back Phase III Wins
Takeda’s oveporexton improved wakefulness, attention and other key narcolepsy endpoints “with a high degree of statistical significance,” according to Jefferies analysts.
July 14, 2025
 · 
2 min read
 · 
Tristan Manalac
vector illustration arrows miss the target board, concept of lost in focus, failure, fail, mistake
Depression
After Three Strikes, Relmada Abandons Depression Drug Esmethadone 
The development saga for the depression molecule has been rocky for years, unable to ease symptoms in multiple late-stage trials.
July 14, 2025
 · 
2 min read
 · 
Tristan Manalac
Contemporary art collage. Giang hand kicking office worker symbolizing dismissal. Unsuccessful employee. Job reduction. Concept of business, career, failure, success, troubles
Rare diseases
Ultragenyx Takes Second Hit as FDA Rejects Gene Therapy for Sanfilippo Syndrome
The FDA cited manufacturing issues but did not flag problems with Ultragenyx’s data package for UX111, with the biotech noting that the regulator found its neurodevelopmental findings for the gene therapy to be “robust.”
July 14, 2025
 · 
2 min read
 · 
Tristan Manalac
Regulatory
FDA Mulls Speedier Reviews to Companies Willing To Lower Drug Costs
Through its recently unveiled Priority Voucher program, the FDA seeks to accelerate the review process for companies that promise to keep prices down.
July 14, 2025
 · 
1 min read
 · 
Tristan Manalac
Pharmaceutical research and new medicine biotechnology or revolutionary medication discovery health concept with prescription pill symbols with 3D illustration elements.
Obesity
Obesity in Focus: ADA Reveals R&D Priorities for Blockbusters-in-Waiting
New data and analyses presented at the American Diabetes Association’s annual meeting highlight the priorities for the next generation of weight loss medicines: muscle preservation, limited side effects and novel targets.
July 14, 2025
 · 
9 min read
 · 
Tristan Manalac
FDA signage at its headquarters in Maryland
FDA
FDA Action Alert: Roche, GSK, Regeneron, More
The FDA has several big-ticket decisions lined up to close out July, including applications in lymphoma, rare diseases and a hormone deficiency, while GSK dares to DREAMM again in multiple myeloma.
July 14, 2025
 · 
7 min read
 · 
Tristan Manalac
Psychedelics
Can Psychedelics Break Through in Depression? Recent Readouts Leave Investors Wanting More
Market reaction to recent readouts from Compass Pathways and Beckley Psytech/atai in treatment-resistant depression speaks to the hurdles psychedelic therapies must clear to quell concerns about commercial viability.
July 14, 2025
 · 
8 min read
 · 
Heather McKenzie
Businessman controlling and monitoring health care system on a digital screen.
Opinion
Tomorrow’s Precision Therapeutics Depend on Precision Diagnostics
Only with the adoption of digital imaging and AI-powered analysis will next-generation precision oncology therapies reach their full potential and ensure no eligible patient is overlooked.
July 14, 2025
 · 
3 min read
 · 
Robert Monroe
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS